Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or observation for 1 year. The pembrolizumab group had a median disease-free survival twice as long as the observation group.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology